GLP-1 Compounding Policy After the Shortage: What Patients Need to Know

As the FDA-declared national shortage of GLP-1 medications resolves, the legal rules shift. Under FDA policy, 503A traditional compounding pharmacies generally may not prepare copies of FDA-approved GLP-1 products once the shortage is resolved unless they meet an individualized patient-specific exception. 503B outsourcing facilities must also stop producing essentially copies of approved GLP-1 drugs when the shortage no longer appears on the FDA drug-shortage list. That means compounded semaglutide and tirzepatide products that were made available because of scarcity may no longer be legally compounded or dispensed simply as lower-cost alternatives.

In most cases, no. Once FDA determines the shortage is resolved, compounded versions that are essentially copies of Wegovy, Ozempic, Zepbound, or Mounjaro are not permitted to be produced for general dispensing. A 503A pharmacy may still compound an individualized preparation pursuant to a valid prescription if it is not essentially a copy of a commercially available product, but routine cash-pay compounded GLP-1 copy products should not be available. If a vendor is still advertising these products broadly after the shortage is resolved, that is a red flag.

Verify four things before using any compounding pharmacy: (1) 503B outsourcing facilities must be registered with FDA and appear on the FDA registered outsourcing facilities list; (2) the pharmacy must hold an active state pharmacy license in the state where it dispenses to you; (3) look for accreditation such as ACHC, PCAB, or another recognized sterile-compounding credential; and (4) the pharmacy should be transparent about the source of its active pharmaceutical ingredient, its sterile-compounding practices, and provide a certificate of analysis on request. Avoid sellers that advertise FDA-approved compounded drugs, refuse to name their pharmacy, or ship from outside the United States.

Start the conversation with your prescriber at least 2 to 4 weeks before your compounded supply runs out. Ask which branded option your insurance covers and whether a prior authorization is needed. Check availability at a local or mail-order pharmacy for Ozempic, Wegovy, Mounjaro, or Zepbound. Compare your out-of-pocket cost, including manufacturer savings programs. Do not stop GLP-1 therapy abruptly without medical guidance, because appetite and blood-sugar control can rebound quickly. If you switch molecules or brands, your prescriber may restart you on a lower dose and titrate up to reduce gastrointestinal side effects.

A 2025 study of real-world patients found the most common reasons for stopping semaglutide or tirzepatide were side effects, cost, supply or access problems, and perceived lack of effect [PMID 41039650]. After the shortage resolves, access problems and compounded-product uncertainty become additional reasons to plan a transition with your clinician rather than an abrupt stop.

No. Compounded GLP-1 drugs are not FDA-approved and have not undergone FDA review for safety, effectiveness, or manufacturing quality. Ozempic, Wegovy, Mounjaro, and Zepbound are manufactured products that have been through FDA approval and inspection. During a shortage, compounded products may have served an access need, but they are not generic equivalents and their concentration, sterility, and purity depend on the compounding pharmacy.